Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer.  Bavituximab, the company's lead immunotherapy candidate, is in late-stage clinical development for the treatment of both lung cancer and breast cancer.
Find out how Bavituximab works and get updates on its clinical trials in the brief report you can read at this link: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
 
 
Amarin Corp. Plc (NASDAQ: AMRN) is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development is focused in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's first product, Vascepa® (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product.
In the brief report you can read at the link, find out about the AMRN lead drug Vascepa and get the company’s 2015 financial figures and guidance for 2016: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
 
 
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system diseases, pain and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease.
Get the information about ANAVEX-2-73, its potential applications and updates on the company’s current Phase II clinical trials in the brief report we’ve posted at this link: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
 
 
Sunshine Biopharma Inc. (OTCQB: SBFM) is a pharmaceutical company focused on drugs for the treatment of various forms of cancer. The company is currently in discussions with investment groups to securing funding for its drug candidate Adva-27a development through Phase I clinical trials. Adva-27a has proven to be effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells.
Read about Adva-27a and its potential, along with the SBFM plans to develop the drug candidate in the brief report you can find at this link: http://broadstreetalerts.com/report-avxl-amrn-avxl-sbfm/
 
 
About Broad Street Alerts
 
We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
 
Safe Harbor Statement
 
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements
 
Compliance Procedure
 
Content is researched, written and reviewed on a best-effort basis by a 3rd party analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below.
Contact: Editor@Broadstreetalerts.com
Source: Broad street alerts